Advertisement

Topics

Companies Related to "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)" [Most Relevant Company Matches] RSS

22:53 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)" found in our extensive corporate database of over 50,000 company records.

Showing "Study Evaluate Efficacy Safety Arbaclofen Placarbil XP19986 Adjunctive" Companies 1–25 of 2,200+

Relevant

ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centrali...


TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...


Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

Hallux Incorporated

Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest th...

Vascular Dynamics, Inc.

Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. Vascular Dynamics was one of nine companies chosen in 2012 by the FDA to participate in the Early Feasibility Study IDE Pilot Program. The company is conducting open-label, controlled, multi...

Coeur Scientific Inc.

Coeur Scientific Inc. is a contract development company committed to providing expert consultations and complete in vivo, in vitro preclinical study management in a state-of-the-art professional environment. These services produce detailed and thorough information on the efficacy and safety of new medical devices, procedures and therapeutic agents. Our primary objective is to deliver quality dat...

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Guildford Clinical Pharmacology

Guildford Clinical Pharmacology Ltd (GCPL) has wide experience of efficient study designs in Phases 1 & 2 and develops new surrogate markers especialy for analgesics, the CNS and gastrointestinal drugs. We can use high tech equipment and the staff to run it correctly; recent examples being: 1) Gamma cameras for colonic transit measurements in a proof of efficacy study on a morphine antagonist an...

Evaluate, Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Its services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTe...

Quintiles Scotland

Safety PharmacologyQuintiles has safety pharmacology services to identify the potential adverse pharmacological effects of new chemical entities prior to first administration to man. Regulatory Safety Pharmacology packages Haemodynamics/ECG studies Cardiac action potential in vitro QT prolongationIon channels (e.g. HERG) Discovery SupportQuintiles pharmacologists can provide support in defining th...

Augmenix, Inc.

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in ...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

CLINICAL RESEARCH LABORATORIES, INC

Clinical Research Laboratories, Inc. (CRL) was incorporated in 1992. Today, CRL operates as an independent contract laboratory providing a wide range of clinical safety and efficacy testing to the cosmetic and pharmaceutical industries. Located in central New Jersey, CRL is dedicated to conducting human clinical test procedures to determine the safety and efficacy of cosmetic, personal care, and O...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...

Dr. Macrene Skin Results

As the Derm-Scientist®, Macrene Alexiades-Armenakas,' M.D., Ph.D., F.A.A.D., esteemed background spanning over 20 years encompasses scientific research and clinical dermatology. The recipient of three Harvard degrees: bachelors of arts (A.B.), medical degree(M.D.) and doctorate(Ph.D.) in genetics, Dr. Macrene has spent years in the laboratory investigating various science fields including plant m...

SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. The company has completed enrollment for and is conducting a Phase 2b clinical trial for its proprietary regenerative medical product SB623 for ...

Naurex, Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues who discovered a new mechanism of action for modulating the NMDA receptor. Naurex has used these discoveries to generate novel chemical drug classes known as glycine site functional partial agonists (GFPAs). Naurex's first GFPA NMDA ...

AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of curren...

Isolagen

Isolagen® Inc., a biotechnology company focused on developing emergent, novel skin and tissue rejuvenation technology for application in certain aesthetic and therapeutic markets. I am pleased to lead Isolagen Inc. as Chairman and Chief Executive Officer. Previously, I served as Chairman, President and CEO of Inamed Corporation, a leading specialty aesthetics company acquired by Allergan Inc. ...

SNBL USA, Ltd.

Headquartered in Everett, WA, SNBL USA, Ltd. offers a unique range of safety assessment services to support the drug development process. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, we offer programs ranging from regulatory toxicology to customized study designs and disease models. Our specialized capabi...

BIOCON, INC.

Since 1978 BIOCON has provided highly reliable, custom small animal research services to the region’s leading biomedical scientists. Whether your study involves small animal housing, breeding and colony management, research study applications, safety testing, custom antibody production or fully-compliant Good Laboratory Practices, BIOCON implements our client’s research initiative with dedicat...

Northfield Laboratories

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. Northfield’s product, PolyHeme®, is a human hemoglobin-based temporary oxygen-carrying red blood cell substitute. PolyHeme® simultaneously restores lost blood volum...

Adamis Pharmaceuticals Corporation

La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial resources toward the development of its Riquent® (abetimus sodium) product candidate, as a treatment for patients with lupus. In February 2009, La Jolla announced that an inde...


More From BioPortfolio on "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks